56 results
Primary:To evaluate the clinical activity of GSK525762 in NUT Midline Carcinoma and other solid tumors.Secondary:Effect of treatment with GSK525762 on tumor growth and survival. Pharmacokinetics of GSK525762. Safety.
Primary Objectives:*To explore whether early abiraterone exposure (AUC) is corre*lated to treatment response after 3 months and 6 months of therapy (primarily based on radiographic response (RECIST re*sponse: SD, PR, CR) and secondary on…
Primary: To evaluate the safety of GSK2849330 in a larger population of subjects in molecularly-defined tumor histology groups at the dose regimen(s) recommended for further exploration in Part 1. Secondary: Clinical benefit, pharmacodynamics,…
The overall objective of this phase I/II three-part study is to evaluate the benefit of 12 weeks once daily dosing with ASP9521 in a population of patients with metastatic castrate resistant prostate cancer (CRPC) who have failed one or more lines…
To assess the safety of a single dose of intravenous EC17 injection in patients with ovarian, lung, breast cancer and parathyroid adenomas. To assess concordance of fluorescent signal and tumor status of resected tissue, in the case of ovarian, lung…
Demonstrate an increase of 2-year overall survival (OS) of 15 % (from 50% to 65 %) vs historical controls of the addition of nitroglycerin to radiotherapy (±chemotherapy) of stage I-IV NSCLC.
Primary: To allow continued use of panobinostat to patients receiving single agent therapy with panobinostat in a Novartis-sponsored study.Secondary: To collect long term data on SAEs.
Non invasive imaging of hypoxia with the aid of PET-scans could help to select the patients having a hypoxic tumor who could be treated with specific anti-hypoxic treatments. The added value of additional anti-hypoxic treatments depends on the…
To determine the test-retest variability of quantitative hypoxia imaging with FAZA-PET, both in untreated subjects (track A) and during radiotherapy (track B). The purpose of this study is to validate FAZA-PET as a selection criterion for…
The first objective is to assess which determinants predict swallowing dysfunction after curative (chemo)radiation. We want to determine the possible relationships between the radiation dose distributions in anatomical structures involved in…
The aim of the study is to investigate the feasibility, safety, toxicity, quality of life (QoL), and regional control of unilateral ENI using SNM with SPECT/CT to select patients with unilateral drainage in lateralized HNSCC treated with primary…
Primary Objectives1. To assess the safety and tolerability of ascending doses of a single IV injection of OTL-0382. To assess the efficacy of ascending doses of a single IV injection of OTL-038 in detecting ovarian, renal cell and endometrial cancer…
This study has been transitioned to CTIS with ID 2024-518046-25-00 check the CTIS register for the current data. Evaluation of the feasibility of intraoperative visualization of penile and tongue tumours using the fluorescent tracer EMI-137.
This study has been transitioned to CTIS with ID 2024-513033-21-00 check the CTIS register for the current data. Primary:• To monitor participants for delayed AEs associated with administration of autologous cells that have been genetically modified…
Cohorts A nd B :The primary objective is to evaluate the objective response rate (ORR) in patients with solid tumors harboring FGFRrearrangements or gastric cancer (including GEJ cancer) harboring FGFR2 amplifications based on independent central…
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
Phase 1 Dose Escalation:Phase 1 Dose Escalation has been completed as of Amendment 6Phase 1 Expansion Primary• To evaluate ORR in cholangiocarcinoma (intra-hepatic [iCCA] or extra-hepatic [eCCA]) patients with tumors harboring FGFR2 gene fusions or…
This study has been transitioned to CTIS with ID 2024-514791-40-00 check the CTIS register for the current data. Based on results from a comparative review (Paoletti 2013), we hypothesize that if the toxicity profile and the PK parameters observed…
The ability to fuse discrete small molecules with different types of pharmacologic activity has created remarkable opportunities in drug discovery and development. Bendamustine itself is a fusion molecule of the nitrogen mustard mechlorethamine and…
This study has been transitioned to CTIS with ID 2024-513627-16-01 check the CTIS register for the current data. Dose escalationPrimary• To determine the RP2D of single-agent petosemtamab in mCRC patients who have progressed on chemotherapy, with or…